61Y Stock Overview
A pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Marinus Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.28 |
| 52 Week High | US$10.10 |
| 52 Week Low | US$0.27 |
| Beta | 1.26 |
| 11 Month Change | -80.68% |
| 3 Month Change | -75.52% |
| 1 Year Change | -94.84% |
| 33 Year Change | -97.32% |
| 5 Year Change | -92.72% |
| Change since IPO | -99.30% |
Recent News & Updates
Recent updates
Shareholder Returns
| 61Y | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -7.8% | -6.1% | -0.2% |
| 1Y | -94.8% | -22.4% | 7.8% |
Return vs Industry: 61Y underperformed the German Pharmaceuticals industry which returned -21.6% over the past year.
Return vs Market: 61Y underperformed the German Market which returned 7.9% over the past year.
Price Volatility
| 61Y volatility | |
|---|---|
| 61Y Average Weekly Movement | 25.2% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 61Y's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 61Y's weekly volatility has increased from 19% to 25% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 166 | Scott Braunstein | marinuspharma.com |
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company’s ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential.
Marinus Pharmaceuticals, Inc. Fundamentals Summary
| 61Y fundamental statistics | |
|---|---|
| Market cap | €16.01m |
| Earnings (TTM) | -€132.60m |
| Revenue (TTM) | €29.70m |
0.5x
P/S Ratio-0.1x
P/E RatioIs 61Y overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 61Y income statement (TTM) | |
|---|---|
| Revenue | US$31.47m |
| Cost of Revenue | US$102.48m |
| Gross Profit | -US$71.01m |
| Other Expenses | US$69.48m |
| Earnings | -US$140.49m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.55 |
| Gross Margin | -225.68% |
| Net Profit Margin | -446.49% |
| Debt/Equity Ratio | -116.5% |
How did 61Y perform over the long term?
See historical performance and comparison